PCI Biotech Holding ASA (0JGL) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi, and welcome to PCI Biotech's first half-year 2024 presentation. My name is Ronny Skuggerahl. With me today is Morten Lur, who is responsible for business development and project manager for our bioprocess project. Let's take a look at our important notice and disclaimer. Agendaen i dag, først operational review, fokus på bioprosessprojektet vårt, så litt rundt finans og outlook, og så til slutt en Q&A session, og jeg oppfordrer dere allerede nå til å sende inn skriftlige spørsmål via webcast-konsolen, sånn at vi er sikre på at vi har dem i hendet før vi kommer så langt. Da I give the floor to Martin. Good morning. Genetic therapies are biological drugs with life-saving potential, where there have been major breakthroughs in the treatment of both blood cancer and hereditary diseases in recent years. Brain gene therapy is divided into two categories, in vivo gene therapy and ex vivo gene therapy. PCI Biotech focuses on in vivo gene therapy, where a so-called viral vector is used to deliver genetic medicine directly to the patient. The genetic medicine recreates a certain function in the body, for example motor skills or vision. Some examples of such gene therapies are Solgensma from Novartis and Luxdurna from Spark Therapeutics. The downside of the medal with these groundbreaking medicines is that they are very expensive and have such a complex production process that it is almost impossible to make them for large patient populations. Improved production is therefore necessary to make gene therapy available to new and larger groups of patients. Let us now take a closer look at why viral vectors are so complicated to produce. There are mainly three reasons. Viral vectors are complex products. 2. Viral vectors must be made of living cells. 3. There is a limited suppl...